Nerve Growth Factor and Diabetic Neuropathic Pain
When it comes to a successful therapy for diabetic neuropathic pain, the key components must include minimal side effects with pain alleviation, and disease modification with nerve regeneration. While current treatments for diabetic neuropathic pain help with pain alleviation, they do not address the underlying disease. This leaves a large unmet need for patients that suffer from diabetic neuropathic pain.
NeuroBo’s approach to NB-01 is designed for a product profile that potentially addresses pain alleviation and underlying mechanisms, with minimal side effects.
With NB-01, there is even the possibility for future expansion into peripheral neuropathic pain, which is pain resulting from damage to peripheral nerves.
According to the Alzheimer’s Association, someone in the United States develops Alzheimer’s disease every 65 seconds. There are currently four approved drugs on the market that manage the symptoms of Alzheimer’s disease, but none of these address disease modification.
In preclinical studies, NB-02 has demonstrated inhibition of acetyl cholinesterase inhibition, as with the current drugs on the market, but more importantly, has also demonstrated inhibition of amyloid-beta plaque formation and inhibition of Tau phosphorylation – both mechanisms implicated to be potential causes of Alzheimer’s disease.